Novel analogs of antitumor agent calixarene 0118: Synthesis, cytotoxicity, click labeling with 2-[18F]fluoroethylazide, and in vivo evaluation

Tilman Läppchen, Ruud P.M. Dings, Raffaella Rossin, Justine F. Simon, Ton J. Visser, Martine Bakker, Priya Walhe, Tiemen Van Mourik, Katia Donato, Judy R. Van Beijnum, Arjan W. Griffioen, Johan Lub, Marc S. Robillard, Kevin H. Mayo, Holger Grüll

Research output: Contribution to journalArticleAcademicpeer-review

16 Citations (Scopus)

Abstract

Calixarene 0118 is a potent anti-angiogenic agent that effectively inhibited tumor growth in preclinical studies, and is currently being evaluated in a phase I clinical trial. We have designed two close mimetics of calixarene 0118 containing a terminal alkynyl-functional group, and developed an optimized semi-automated procedure for radiolabeling with 2-[18F]fluoroethylazide using click chemistry. Following semi-preparative HPLC purification and formulation, the lower-rim modified analog [18F]6 and the equatorially labeled [18F]13 were obtained in >97% radiochemical purity and overall decay-corrected isolated radiochemical yields of 18.7 ± 2.7% (n = 4) and 10.2 ± 5.0% (n = 4), respectively, in a total synthesis time of about 2 h. Preliminary in vivo studies in nude mice bearing human tumor xenografts revealed highest accumulation of both tracers in the liver, followed by spleen, kidney, lung and bone, with no substantial uptake in the tumor. Still, these first-in-class radiotracers are a valuable tool for pharmacokinetic profiling and improvement of calixarene-based anti-angiogenic therapeutics in the future, as similar radiolabeling strategies may be applied to other compounds in the calixarene series. The cold reference compounds of the radiotracers were characterized in terms of cytotoxicity and anti-proliferative effects on HUVEC cells and on MA148 human ovarian carcinoma cells, along with the respective precursors, a small series of 0118 analogs modified with short-chain linear alkyl substituents, and a PEG3-spaced calixarene dimer. While all of the new analogs proved at least equipotent to parent 0118, some of them inhibited HUVEC and MA148 cell growth almost 4- and 10-fold more effectively, rendering these analogs promising candidates for further evaluation in anti-angiogenic cancer therapy.

Original languageEnglish
Pages (from-to)279-295
Number of pages17
JournalEuropean Journal of Medicinal Chemistry
Volume89
DOIs
Publication statusPublished - 7 Jan 2015

Fingerprint

Calixarenes
Cytotoxicity
Antineoplastic Agents
Labeling
Tumors
Human Umbilical Vein Endothelial Cells
Neoplasms
Bearings (structural)
Click Chemistry
Clinical Trials, Phase I
Pharmacokinetics
Cell growth
Growth
Heterografts
Nude Mice
Dimers
Liver
Functional groups
Purification
Bone

Keywords

  • Anti-angiogenic therapy
  • Calixarene
  • Click chemistry
  • Compound 0118
  • Fluorine-18
  • Pet imaging

Cite this

Läppchen, Tilman ; Dings, Ruud P.M. ; Rossin, Raffaella ; Simon, Justine F. ; Visser, Ton J. ; Bakker, Martine ; Walhe, Priya ; Van Mourik, Tiemen ; Donato, Katia ; Van Beijnum, Judy R. ; Griffioen, Arjan W. ; Lub, Johan ; Robillard, Marc S. ; Mayo, Kevin H. ; Grüll, Holger. / Novel analogs of antitumor agent calixarene 0118 : Synthesis, cytotoxicity, click labeling with 2-[18F]fluoroethylazide, and in vivo evaluation. In: European Journal of Medicinal Chemistry. 2015 ; Vol. 89. pp. 279-295.
@article{e15e1e8bb4a9444991982434180594d6,
title = "Novel analogs of antitumor agent calixarene 0118: Synthesis, cytotoxicity, click labeling with 2-[18F]fluoroethylazide, and in vivo evaluation",
abstract = "Calixarene 0118 is a potent anti-angiogenic agent that effectively inhibited tumor growth in preclinical studies, and is currently being evaluated in a phase I clinical trial. We have designed two close mimetics of calixarene 0118 containing a terminal alkynyl-functional group, and developed an optimized semi-automated procedure for radiolabeling with 2-[18F]fluoroethylazide using click chemistry. Following semi-preparative HPLC purification and formulation, the lower-rim modified analog [18F]6 and the equatorially labeled [18F]13 were obtained in >97{\%} radiochemical purity and overall decay-corrected isolated radiochemical yields of 18.7 ± 2.7{\%} (n = 4) and 10.2 ± 5.0{\%} (n = 4), respectively, in a total synthesis time of about 2 h. Preliminary in vivo studies in nude mice bearing human tumor xenografts revealed highest accumulation of both tracers in the liver, followed by spleen, kidney, lung and bone, with no substantial uptake in the tumor. Still, these first-in-class radiotracers are a valuable tool for pharmacokinetic profiling and improvement of calixarene-based anti-angiogenic therapeutics in the future, as similar radiolabeling strategies may be applied to other compounds in the calixarene series. The cold reference compounds of the radiotracers were characterized in terms of cytotoxicity and anti-proliferative effects on HUVEC cells and on MA148 human ovarian carcinoma cells, along with the respective precursors, a small series of 0118 analogs modified with short-chain linear alkyl substituents, and a PEG3-spaced calixarene dimer. While all of the new analogs proved at least equipotent to parent 0118, some of them inhibited HUVEC and MA148 cell growth almost 4- and 10-fold more effectively, rendering these analogs promising candidates for further evaluation in anti-angiogenic cancer therapy.",
keywords = "Anti-angiogenic therapy, Calixarene, Click chemistry, Compound 0118, Fluorine-18, Pet imaging",
author = "Tilman L{\"a}ppchen and Dings, {Ruud P.M.} and Raffaella Rossin and Simon, {Justine F.} and Visser, {Ton J.} and Martine Bakker and Priya Walhe and {Van Mourik}, Tiemen and Katia Donato and {Van Beijnum}, {Judy R.} and Griffioen, {Arjan W.} and Johan Lub and Robillard, {Marc S.} and Mayo, {Kevin H.} and Holger Gr{\"u}ll",
year = "2015",
month = "1",
day = "7",
doi = "10.1016/j.ejmech.2014.10.048",
language = "English",
volume = "89",
pages = "279--295",
journal = "European Journal of Medicinal Chemistry",
issn = "0223-5234",
publisher = "Springer",

}

Läppchen, T, Dings, RPM, Rossin, R, Simon, JF, Visser, TJ, Bakker, M, Walhe, P, Van Mourik, T, Donato, K, Van Beijnum, JR, Griffioen, AW, Lub, J, Robillard, MS, Mayo, KH & Grüll, H 2015, 'Novel analogs of antitumor agent calixarene 0118: Synthesis, cytotoxicity, click labeling with 2-[18F]fluoroethylazide, and in vivo evaluation', European Journal of Medicinal Chemistry, vol. 89, pp. 279-295. https://doi.org/10.1016/j.ejmech.2014.10.048

Novel analogs of antitumor agent calixarene 0118 : Synthesis, cytotoxicity, click labeling with 2-[18F]fluoroethylazide, and in vivo evaluation. / Läppchen, Tilman; Dings, Ruud P.M.; Rossin, Raffaella; Simon, Justine F.; Visser, Ton J.; Bakker, Martine; Walhe, Priya; Van Mourik, Tiemen; Donato, Katia; Van Beijnum, Judy R.; Griffioen, Arjan W.; Lub, Johan; Robillard, Marc S.; Mayo, Kevin H.; Grüll, Holger.

In: European Journal of Medicinal Chemistry, Vol. 89, 07.01.2015, p. 279-295.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Novel analogs of antitumor agent calixarene 0118

T2 - Synthesis, cytotoxicity, click labeling with 2-[18F]fluoroethylazide, and in vivo evaluation

AU - Läppchen, Tilman

AU - Dings, Ruud P.M.

AU - Rossin, Raffaella

AU - Simon, Justine F.

AU - Visser, Ton J.

AU - Bakker, Martine

AU - Walhe, Priya

AU - Van Mourik, Tiemen

AU - Donato, Katia

AU - Van Beijnum, Judy R.

AU - Griffioen, Arjan W.

AU - Lub, Johan

AU - Robillard, Marc S.

AU - Mayo, Kevin H.

AU - Grüll, Holger

PY - 2015/1/7

Y1 - 2015/1/7

N2 - Calixarene 0118 is a potent anti-angiogenic agent that effectively inhibited tumor growth in preclinical studies, and is currently being evaluated in a phase I clinical trial. We have designed two close mimetics of calixarene 0118 containing a terminal alkynyl-functional group, and developed an optimized semi-automated procedure for radiolabeling with 2-[18F]fluoroethylazide using click chemistry. Following semi-preparative HPLC purification and formulation, the lower-rim modified analog [18F]6 and the equatorially labeled [18F]13 were obtained in >97% radiochemical purity and overall decay-corrected isolated radiochemical yields of 18.7 ± 2.7% (n = 4) and 10.2 ± 5.0% (n = 4), respectively, in a total synthesis time of about 2 h. Preliminary in vivo studies in nude mice bearing human tumor xenografts revealed highest accumulation of both tracers in the liver, followed by spleen, kidney, lung and bone, with no substantial uptake in the tumor. Still, these first-in-class radiotracers are a valuable tool for pharmacokinetic profiling and improvement of calixarene-based anti-angiogenic therapeutics in the future, as similar radiolabeling strategies may be applied to other compounds in the calixarene series. The cold reference compounds of the radiotracers were characterized in terms of cytotoxicity and anti-proliferative effects on HUVEC cells and on MA148 human ovarian carcinoma cells, along with the respective precursors, a small series of 0118 analogs modified with short-chain linear alkyl substituents, and a PEG3-spaced calixarene dimer. While all of the new analogs proved at least equipotent to parent 0118, some of them inhibited HUVEC and MA148 cell growth almost 4- and 10-fold more effectively, rendering these analogs promising candidates for further evaluation in anti-angiogenic cancer therapy.

AB - Calixarene 0118 is a potent anti-angiogenic agent that effectively inhibited tumor growth in preclinical studies, and is currently being evaluated in a phase I clinical trial. We have designed two close mimetics of calixarene 0118 containing a terminal alkynyl-functional group, and developed an optimized semi-automated procedure for radiolabeling with 2-[18F]fluoroethylazide using click chemistry. Following semi-preparative HPLC purification and formulation, the lower-rim modified analog [18F]6 and the equatorially labeled [18F]13 were obtained in >97% radiochemical purity and overall decay-corrected isolated radiochemical yields of 18.7 ± 2.7% (n = 4) and 10.2 ± 5.0% (n = 4), respectively, in a total synthesis time of about 2 h. Preliminary in vivo studies in nude mice bearing human tumor xenografts revealed highest accumulation of both tracers in the liver, followed by spleen, kidney, lung and bone, with no substantial uptake in the tumor. Still, these first-in-class radiotracers are a valuable tool for pharmacokinetic profiling and improvement of calixarene-based anti-angiogenic therapeutics in the future, as similar radiolabeling strategies may be applied to other compounds in the calixarene series. The cold reference compounds of the radiotracers were characterized in terms of cytotoxicity and anti-proliferative effects on HUVEC cells and on MA148 human ovarian carcinoma cells, along with the respective precursors, a small series of 0118 analogs modified with short-chain linear alkyl substituents, and a PEG3-spaced calixarene dimer. While all of the new analogs proved at least equipotent to parent 0118, some of them inhibited HUVEC and MA148 cell growth almost 4- and 10-fold more effectively, rendering these analogs promising candidates for further evaluation in anti-angiogenic cancer therapy.

KW - Anti-angiogenic therapy

KW - Calixarene

KW - Click chemistry

KW - Compound 0118

KW - Fluorine-18

KW - Pet imaging

UR - http://www.scopus.com/inward/record.url?scp=84908551410&partnerID=8YFLogxK

U2 - 10.1016/j.ejmech.2014.10.048

DO - 10.1016/j.ejmech.2014.10.048

M3 - Article

C2 - 25462244

AN - SCOPUS:84908551410

VL - 89

SP - 279

EP - 295

JO - European Journal of Medicinal Chemistry

JF - European Journal of Medicinal Chemistry

SN - 0223-5234

ER -